Findings from these studies suggest that IgA antibodies against EBV capsid antigen (VCA/IgA) is a biomarker associated with the risk of NPC development and using this marker as a screening tool for NPC is feasible [43]–[44], [46]–[47]. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.